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Background: Previous studies have shown that the arterial wall is a potential source of
inflammatory markers in COPD. Here, we sought to compare the expression of acute phase
reactants (APRs) in COPD patients and controls both at the local (pulmonary arteries and
lung parenchyma) and systemic (peripheral blood leukocytes and plasma) compartments.
Methods: Consecutive patients undergoing elective surgery for suspected primary lung
cancer were eligible for the study. Patients were categorized either as COPD or control
group based on the spirometry results. Pulmonary arteries and lung parenchyma sections,
peripheral blood leukocytes, and plasma samples were obtained from all participants. Gene
expression levels of C-reactive protein (CRP) and serum amyloid A (SAA1, SAA2, and
SAA4) were evaluated in tissue samples and peripheral blood leukocytes by reverse
transciption-PCR. Plasma CRP and SAA protein levels were measured by enzyme-linked
immunosorbent assays. Proteins were evaluated in paraffin-embedded lung tissues by
immunohistochemistry.
Results: A total of 40 patients with COPD and 62 controls were enrolled. We did not find
significant differences in the gene expression between COPD and control group. Both CRP
and SAAwere overexpressed in the lung parenchyma compared with pulmonary arteries and
peripheral blood leukocytes. The expression of SAA was significantly higher in the lung
parenchyma than in the pulmonary artery (2-fold higher for SAA1 and SAA4, P=0.015 and
P<0.001, respectively; 8-fold higher for SAA2, P<0.001) and peripheral blood leukocytes
(16-fold higher for SAA1, 439-fold higher for SAA2, and 5-fold higher for SAA4; P<0.001).
No correlation between plasma levels of inflammatory markers and their expression in the
lung and peripheral blood leukocytes was observed.
Conclusions: The expression of SAA in lung parenchyma is higher than in pulmonary
artery and peripheral blood leukocytes. Notably, no associations were noted between lung
expression of APRs and their circulating plasma levels, making the leakage of inflammatory
proteins from the lung to the bloodstream unlikely. Based on these results, other potential
sources of systemic inflammation in COPD (eg, the liver) need further scrutiny.
Keywords: COPD, inflammation, C-reactive protein, serum amyloid A, arterial wall,
parenchyma
Introduction
Although the presence of systemic inflammation has been extensively documented in
patients with COPD, its exact sources are still unclear.1 Moreover, the question as to
whether the systemic inflammatory response may influence the clinical manifestations
and the expression of different COPD phenotypes remains open.2
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C-reactive protein (CRP) and serum amyloid A (SAA)
are among the most common acute phase reactants (APRs)
found to be increased in COPD,3,4 even though their
biological sources have not been yet identified.5 It has
been hypothesized that the excess production of local
inflammatory mediators in the pulmonary compartment
may spill over into the systemic circulation.6 However,
this possibility is contradicted by the lack of correlation
between local and systemic expression of inflammatory
biomarkers in COPD.7 Moreover, markers of inflammation
in the induced sputum did not show a significant associa-
tion with their plasma levels.6
Previous investigations conducted in normal tissues as
well as animal and in vitro studies demonstrated that lung
tissues are able to synthesize and secrete APRs.3,8,9 We
have previously shown that bronchi and the lung parench-
yma are able to synthesize CRP and SAA in COPD as
compared with smokers who did not develop the disease
(control group),10 with potential distinct roles for fibro-
blasts, epithelial cells, and macrophages.11 Notably, our
immunohistochemical observations revealed an increased
expression of APRs in the arterial wall of pulmonary ves-
sels. Therefore, it is possible that blood vessels or cells may
be responsible for these observations. The role of pulmon-
ary arteries and peripheral blood leukocytes as a potential
source of systemic inflammatory markers in COPD has not
yet been evaluated. The potential involvement of the arterial
wall and/or peripheral blood leukocytes in COPD inflam-
mation would also explain the well-known association of
this condition with adverse cardiovascular events.12
We therefore designed the current case-control study to
compare the expression of APRs in COPD patients and
controls both at the local (pulmonary arteries and lung
parenchyma) and systemic (peripheral blood leukocytes
and plasma) compartments.
Methods
Study participants
Consecutive patients with suspected primary lung cancer
who were scheduled for elective pneumectomy or lobect-
omy were eligible. Patients were approached for the study
the day before scheduled surgery. Exclusion criteria were as
follows: 1) age <40 years, 2) a history of acute respiratory
infections in the previous 2months, 3) a previously diag-
nosed neoplasm, 4) treatment with radiotherapy and/or che-
motherapy, 5) presence of chronic inflammatory diseases,
and 6) autoimmune diseases. The amount of time spent
between the opening of the cutaneous layer and the extrac-
tion of the anatomical sample was measured in all partici-
pants. Cases with an elapsed time >3 hrs were excluded
because of the potential surgery-related increase in inflam-
matory markers. Patients had their medical records checked
to ensure that they recently underwent a lung function test.
Participants with a /FVC ratio <0.7 post-bronchodilator were
considered as having COPD. The patients were classified
according to the stage of the disease following the instruc-
tions of the GOLD. All of the remaining was considered
controls. The study participants completed a standardized
questionnaire focusing on their medical history, tobacco
smoking habits, and current use of drugs. The Charlson-
age comorbidity index is a measure of comorbidity that
was developed as a prospectively applicable method for
classifying comorbid conditions which might alter the risk
of morality for use in longitudinal studies.13 The TNM
staging of the primary lesion14 and the surgical approach
were also recorded. A lung specimen was submitted for
microbiological examination before surgical resection to
evaluate microbial colonization. Microbiological samples
obtained with bronchoscopy were also examined. After sur-
gery, a section of the lung parenchyma and the largest
available section of the resected pulmonary artery were
collected for further study. Samples that were most distally
located from the primary lesion were identified and imme-
diately processed. The remaining anatomical sample was
submitted for pathological diagnosis of the primary lesion.
Peripheral venous blood samples were collected before sur-
gery in all participants. This study was conducted in accor-
dance with the Declaration of Helsinki.
Gene expression levels in tissues and
blood
Expression of inflammatory markers in tissues and periph-
eral blood leukocytes was analyzed using reverse transcrip-
tion quantitative PCR(RT-qPCR), a method consisting of
three steps (RNA extraction, reverse transcription to cDNA,
and gene amplification). RNA was isolated from fresh tis-
sues with a TriSure kit (Bioline, London, UK). Samples
subsequently underwent DNase treatment using RNase-free
DNase (QIAGEN GmbH, Hilden, Germany) and cDNA
was synthesized using an iScript™ cDNA synthesis kit
(Bio-Rad, Hercules, CA, USA). Each 25 µL amplification
reaction mixture comprised 5 µL cDNA (10 ng/µL), 12.5
µL SYBR® Green PCR Master Mix (Stratagene, La Jolla,
CA, USA) and 7.5 µL primers/H2O. RT-qPCR was
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performed on an Applied Biosystems® 7900 Real-Time
PCR System (Life Technologies, Grand Island, NY, USA)
under the following cycling conditions: 95 ºC for 15 s, 60ºC
for 30 s, and 72ºC for 40 s, 40 cycles. 18S ribosomal RNA
(rRNA) expression was used as an internal control for
normalization of target gene expression. The list of primers
used to amplify the genes of interest is provided in Table 1.
Three tightly linked SAA genes have been identified in
humans (SAA1, SAA2, and SAA4). Their synthesis is
triggered by proinflammatory cytokines released upon acti-
vation of monocytes/macrophages.15
Measurements of plasma inflammatory
markers
Blood samples (5 mL) were collected by venipuncture in
K3-EDTA tubes (Vacuette, Bio-One GmbH, Greiner,
Austria). Samples were immediately centrifuged, and
plasma aliquots were stored at −80°C until immediately
before analysis. Plasma CRP (R&D System, Minneapolis,
MN, USA) and SAA (Anogen, Mississauga, Ontario,
Canada) levels were measured using commercially available
enzyme immunoassay kits according to the manufacturers’
protocol.
Immunohistochemistry
Tissue blocks from the subpleural parenchyma (paying atten-
tion to avoid areas involved by the tumor) were fixed in 10%
formalin and embedded in paraffin. Five-μm-thick sections
were prepared for immunohistochemical analysis. Mouse
monoclonal antibodies against SAA1 (Novus Biologicals,
Cambridge, UK) and CRP (Abcam, Cambridge UK) were
used. Antigen retrieval was achieved by microwave heat
treatment in citrate buffer (Dako, Glostrup, Denmark) at
98°C for 15 mins. The bound antibody was developed with
diaminobenzidine using a Dako Envision staining kit
(K4065) according to manufacturer’s recommendations.
Stained sections were observed under light microscope by
two independent observers. All immunohistochemical stu-
dies included appropriate standard quality controls. As
a negative control, immunohistochemistry was performed
using secondary antibodies without the primary antibody.
Statistical analysis
Means and SDs for continuous variables and frequencies and
percentages for categorical variables were estimated. Relative
gene expression values were evaluated with the 2−ΔΔCt
method16 to compare COPD and control group, and accord-
ing to the anatomical location. The Student’s t-test was used
to test for differences in continuous variables between COPD
patients and controls. Categorical data were compared with
the χ2 test. The associations between tissue gene expression
and plasma levels of inflammatory biomarkers were analyzed
with the Spearman’s rank correlation coefficient. Analyses
were adjusted for gender and pack-years smoked. All testing
hypotheses were performed at a 5% level of significance
(two-tailed), using the statistical software IBM SPSS
Statistics version 20.0 (IBM Corporation, Somers, NY, USA).
Results
Patients and procedures
Forty patients with COPD were included in the study. The
main characteristics of the study participants are summar-
ized in Table 2. The surgical procedures consisted of pneu-
mectomies (17.6%), lobectomies (78.4%), and atypical
resections (4%). Operations were performed in the right
and left hemi-thorax in 54.9% and 45.1% of the patients,
respectively. Squamous cell (epidermoid) carcinoma
(42.2%) and adenocarcinomas (31.4%) were the most com-
mon histological types. The results of pathological examina-
tion revealed no malignancies in 7.8% of the study patients.
Eleven patients were in Stage I, 24 in Stage II and 5 in
Stage III.
Expression of acute phase reactants in the
lung parenchyma
CRP and SAA gene expression in the lung parenchyma
was higher in COPD patients than in controls (Figure 1A);
Table 1 Primers used for reverse transcription quantitative PCR
Gene Forward primer Reverse primer
18S 5ʹ-TGAAATATCCAGAACATCTTA-3’ 5ʹ-GCAAAATTTATTGTCCCATCAT-3’
CRP 5ʹ-GTGTTTCCCAAAGAGTCGGATA-3’ 5ʹ-CCACGGGTCGAGGACAGTT-3’
SAA1 5ʹ-ATCAGCGATGCCAGAGAGAAT-3’ 5ʹ-GTGATTGGGGTCTTTGCCA-3’
SAA2 5ʹ-AGCCAATTACATCGGCTCAG-3’ 5ʹ-ATTTATTGGCAGCCTGATCG-3’
SAA4 5ʹ-GTCCAACGAGAAAGCTGAGG-3’ 5ʹ-AGTGACCCTGTGTCCCTGTC-3’
Dovepress Arellano-Orden et al
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however, the expression did not differ significantly
between the two groups (P>0.05). In the lung parenchyma,
we found significant positive correlations between the
expression of CRP with SAA1 and SAA4; SAA1 with
SAA2 and SAA4; and SAA2 with SAA4 (Table 3).
Significant differences in terms of SAA4 expression were
observed between controls and GOLD III COPD
(P=0.034), as well as between GOLD II and GOLD III
COPD (P=0.044). SAA4 expression in the lung parench-
yma increased in parallel with the severity of the disease
(Figure 1B).
Expression of acute phase reactants in the
pulmonary artery
CRP expression in the pulmonary artery was higher in COPD
patients than in controls (Figure 2A). Moreover, SAA2
expression was 100% higher in COPD patients than in
controls (P=0.028; Figure 2A). In the pulmonary artery, we
found significant positive correlations between the expres-
sion of CRP and SAA1, 2 and 4, as well as between SAA1
and SAA2 (Table 3). Significant differences in terms of
SAA2 expression were observed between resistant smokers
and GOLD I COPD patients (P=0.010), as well as between
GOLD I and GOLD II COPD (P=0.012; Figure 2B).
Expression of acute phase reactants in
peripheral blood leukocytes
Expression of CRP, SAA1, and SAA4 in peripheral blood
leukocytes was found to differ significantly between COPD
patients and controls. In line with the results obtained in the
pulmonary artery, SAA2 expression was twofold higher in
COPD patients than in controls (Figure 3A).
There was a significant positive correlation between
the expression of CRP and SAA1 and SAA4; and SAA1
Table 2 General characteristics of the study participants
Control group (n=62) COPD patients (n=40) P-value*
Males (n) 48 (77.4%) 37 (92.5%) 0.029
Age (years) 64.4±13.5 67.4±8.01 NS
Tobacco history (pack-years) 43.5±34.7 69.7±33.1 0.001
Current smokers/former smokers 13/27 17/45 NS
Charlson-age index 4.9±2.2 5.7±1.7 NS
FVC (%) 98.7±20.45 91.6±19 NS
FEV1 (%) 94.0±19.89 69.0±18.4 <0.001
FEV1/FVC (%) 77.1±6.9 59.0±9.7 <0.001
Oral steroids 77.1±6.9 7 (17.5%) <0.001
Combinations including an inhaled corticosteroid 0 (0%) 14 (35.0%) 0.029
Notes: Data are expressed as means and SDs for continuous variables and frequencies and percentages for categorical variables. *P-values were calculated with the Student’s
t-test (continuous variables) or the χ2 test (categorical variables).
Abbreviation: NS, not significant.
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Figure 1 Gene expression in COPD patients and control group. Gene expression of acute phase reactants in resistant smokers (controls) and COPD patients in lung
parenchyma (panel A). SAA4 expression profile in the lung parenchyma according to COPD stage (Panel B). I, GOLD I COPD; II, GOLD II COPD; III, GOLD III COPD. No
statistically significant differences were identified (P>0.05).
Abbreviations: CNT, resistant smokers (controls); SAA, serum amyloid A.
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and SAA4 (Table 3). We found significant differences
between GOLD I COPD and controls in terms of SAA1
(P=0.037) and SAA4 (P=0.018) expression (Figure 3B
and C). In addition, significant differences in terms of
SAA4 expression were observed between GOLD I and
GOLD II COPD (P=0.030).
Comparison of acute phase reactants
expression in different tissues
We then performed a comparison of APRs expression in
the lung parenchyma, pulmonary artery, and peripheral
blood leukocytes (Figure 4). The expression of SAA was
significantly higher in the lung parenchyma than in the
pulmonary artery (2-fold higher for SAA1 and SAA4,
P=0.015 and P<0.001, respectively; eightfold higher for
SAA2, P<0.001) and peripheral blood leukocytes (16-fold
higher for SAA1, 439-fold higher for SAA2, and fivefold
higher for SAA4; P<0.001). Compared with peripheral
blood leukocytes, the expression of SAA was significantly
higher in the pulmonary artery (eightfold higher for SAA1,
P<0.001; 50-fold higher for SAA2, P<0.001; and 2.3-fold
higher for SAA4, P=0.019). However, no differences in
CRP expression were observed in the lung parenchyma,
pulmonary artery, and peripheral blood leukocytes. All
findings were maintained after adjusting for gender and
pack-years smoked. We failed to identify significant dif-
ferences in the APRs expression according to the use of
treatment.
Correlations between acute phase
reactants expression in different tissues
Significant positive correlations were identified in the dif-
ferent tissues (Table 4). These findings were maintained
after adjusting for gender and pack-years smoked. We
failed to identify significant differences in the APRs
expression according to the use of treatment.
Associations between acute phase
reactants gene expression and their
plasma concentrations
Plasma CRP showed a trend toward higher levels in
COPD patients (4.4±1.73 mg/mL) than in control group
(3.8±2.04 mg/mL, P>0.05). SAA concentrations in plasma
were significantly higher in COPD patients (5.6±1.3 mg/
mL) than in controls (4.6±21 mg/mL, P=0.031).
A significant positive association between plasma CRP
Table 3 Correlations between expressions of acute phase
reactant
Pulmonary
parenchyma
Pulmonary
artery
Peripheral
blood
leukocytes
CRP-SAA1
mRNA
r=0.448
P<0.001
r=0.314
P=0.001
r=0.510
P<0.001
CRP-SAA2
mRNA
r=0.105
P=NS
r=0.229
P=0.020
r=0.163
P=NS
CRP-SAA4
mRNA
r=0.496
P<0.001
r=0.320
P=0.001
r=0.394
P<0.001
SAA1-SAA2
mRNA
r=0.508
P<0.001
r=0.513
P<0.001
r=0.101
P=NS
SAA1-SAA4
mRNA
r=0.609
P<0.001
r=0.170
P=NS
r=0.744
P<0.001
SAA2-SAA4
mRNA
r=0.4290
P<0.001
r=−0.001
P=NS
r=0.019
P=NS
Note: Correlations were calculated using the Spearman’s rank correlation coefficient.
Abbreviations: CRP,C-reactive protein; SAA, serum amyloid A
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Figure 2 Gene expression in COPD patients and control group. Gene expression of acute phase reactants in resistant smokers (controls) and COPD patients in pulmonary
artery (panel A). SAA2 expression profile in the pulmonary artery according to COPD stage (B). I, GOLD I COPD; II, GOLD II COPD; III, GOLD III COPD. No statistically
significant differences were identified (P>0.05).
Abbreviations: CNT, resistant smokers (controls); SAA, serum amyloid A.
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and SAA levels was evident (P=0.617, P<0.001).
However, there was no significant correlation between
plasma levels of APRs and their gene expression in the
lung parenchyma, pulmonary artery, and peripheral blood
leukocytes. SAA levels increased in parallel with the
severity of COPD (Figure 5A) and CRP levels increased
with the stage of the disease however these differences
were not significant (Figure 5B).
Immunohistochemistry
Immunohistochemistry revealed an increased expression of
both CRP and SAA in the lung tissue of COPD patients as
compared to controls. As shown in Figure 6, staining was
chiefly captured by the small vessel wall, most markedly
for SAA.
Discussion
In the current study, we performed a comparison of APRs
expression in the lung parenchyma, pulmonary artery, and
peripheral blood leukocytes of COPD patients. We also
measured plasma CRP and SAA concentrations with the
goal of establishing whether significant associations exist
with their tissue gene expression. Our results indicate that
the expression of ARPs is higher in the lung compared than
in peripheral blood. Notably, we also observed that both
SAA and CRP expression is more pronounced in the lung
parenchyma than in the pulmonary artery. However, no
association was found between the expression of inflamma-
tory molecules in the lung and their circulating plasma
levels.
Previous studies have consistently shown that COPD
inflammation is not limited to the airways and lung,17 but
it can also be found at the systemic level.18 Although
increased circulating levels of CRP, IL-6, IL-8, and
tumor necrosis factor-α have been reported in COPD
patients,19,20 the exact sources of proinflammatory mole-
cules in this clinical entity remain unclear. The most
widely accepted model explaining systemic inflammation
in COPD postulates that the excess production of local
inflammatory mediators in the pulmonary compartment
may spill over into the systemic circulation.6 CRP is
a well-known biomarker of both airflow obstruction21
and systemic inflammation,22 but less data are available
on SAA as an inflammatory biomarker in COPD.
Although our current findings generally indicate a more
marked inflammatory reaction at the local rather than the
systemic level, it seems that the lack of correlation with
serum levels do not support the spillover hypothesis.
The compartmentalization of CRP and SAA gene expres-
sion is a key factor that needs to be considered when
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analyzing inflammatory biomarkers in COPD. Although the
disease is characterized by marked inflammation of the air-
ways, lung parenchyma, and pulmonary vasculature,23 the
anatomical involvement may show a significant interindivi-
dual variability that ultimately results in different disease
phenotypes.24,25 Aortic endothelial cells may secrete CRP26
and SAA has been shown to be expressed in the
endothelium.27 However, no studies to date have focused
on the potential role of the pulmonary vascular bed as
a source of systemic inflammation in COPD. Our results
indicate that SAA expression in COPD patients is higher in
the lung parenchyma than in the pulmonary artery. In
a previous immunohistochemical investigation, we have
shown that SAA and CRP in COPD are both expressed in
the pulmonary vessel wall.10 Here, we expanded our pre-
vious observations by assessing their gene expression levels
both in the lung and blood compartments. The higher expres-
sion levels of SAA in the lung parenchyma could be ascribed
to small vessels (capillaries), which showed the most marked
staining on immunohistochemistry. Interestingly, APRs were
under-expressed in PBL from COPD as compared to con-
trols. Although the differences are not significant, our inter-
pretation is that probably the blood is a bad candidate as
a potential contributor of systemic inflammation in COPD.
Some caveats of the current study merit comment.
First, although the number of patients may be
a limitation, the groups were balanced in the number of
patients to make groups comparable in sample
size. Second, quantification of mRNA does not provide
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Figure 4 Comparison of acute phase reactants gene expression levels in different tissues (blood cells, pulmonary artery, and lung parenchyma) of COPD patients. Panel (A):
CRP expression; panel (B): SAA2 expression; panel (C): SAA1 expression and panel (D): SAA4 expression.
Abbreviations: CRP, C-reactive protein; SAA, serum amyloid A.
Table 4 Correlations between different tissues
r p
CRP parenchyme-CRP artery 0.195 0.04
SAA1 parenchyme-SAA1 leukocytes 0.743 <0.001
SAA4 parenchyme-SAA4 leukocytes 0.980 <0.001
SAA1 parenchyme-SAA4 leukocytes 0.758 <0.001
SAA4 parenchyme-SAA1 leukocytes 0.966 <0.001
Note: Correlations were calculated using the Spearman’s rank correlation coefficient.
Abbreviations: CRP, C-reactive protein; SAA, serum amyloid A.
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information on the final production of a functional protein;
also the methods used to analyze the gene expression and
proteins are to relative quantification, not absolute. Third,
numerous APRs (including CRP and SAA) can be synthe-
sized in the liver, an organ which was not specifically
investigated in the current report. Ji and coworkers28
have previously studied the inflammatory activity in dif-
ferent compartments (eg, saliva, sputum, bronchoalveolar
lavage, and serum/blood) of COPD patients stratified
according to their smoking status. The results were
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Figure 5 Plasma concentrations of serum amyloid A (SAA) (panel A) and CRP (panel B) in CNTs and patients with different stages of COPD.
Abbreviations: CRP, C-reactive protein; CNT, resistant smokers (controls).
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DC
Figure 6 Immunostaining of C-reactive protein (CRP) and serum amyloid A (SAA) in lung biopsies of patients. Pulmonary parenchyma stained with CRP of a COPD (panel
A) and control (panel B). Pulmonary parenchyma stained with SAA of COPD patient (panel C) and control patients (panel D). Scale bar represents 100 μm in each case.
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adjusted for gender and pack-years smoked because had
significant differences in both groups, these not occur for
BMI or age. The paper of BMI is especially relevant, since
previous reports have informed about this potential asso-
ciation in different clinical conditions.29 In our cohort,
however, we were not able to show this relationship. The
authors identified several associations between different
inflammatory markers both at the local and systemic
level. Further studies of the inflammatory responses in
various compartments (eg, liver, sputum, or saliva) will
be necessary to identify other potential sources of systemic
inflammation in COPD.
COPD is a heterogeneous disorder defined by the pul-
monary function test. The pathogenesis would be different
between subgroups such as the chronic bronchitis and
pulmonary emphysema. Nevertheless, we had not differ-
enced by phenotypes, specifically, we had not determinate
the grade of emphysema, but all patients had centrilobular
emphysema. Other limitation of our study is that the
enrolled patients were all under surgery for suspected
primary lung cancer and the number of patients in all
groups is different, being the number of COPD patients
in stage 3 small.
Conclusions
The inflammatory burden of COPD seems to be higher
in the lung parenchyma than pulmonary arteries and
peripheral blood leukocytes. Notably, no associations
were noted between lung expression of APRs and their
circulating plasma levels, making the leakage of inflam-
matory proteins from the lung to the bloodstream unli-
kely. Based on these results, other potential sources of
systemic inflammation in COPD (eg, the liver) need
further scrutiny.
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